* Martek Biosciences Corp., of Columbia, Md., said Merck & Co., ofWhitehouse Station, N.J., renewed its agreement for screeningMartek's library of microalgae extracts for potential human andanimal drugs and for agricultural applications. Financial terms werenot disclosed. Martek said it has 2,500 organisms in its library.
* Neurobiological Technologies Inc., of Richmond, Calif., afterpricing a public offering in late January 1996 and then postponing it,completed the sale of 2.2 million shares at $3.25 per share for grossproceeds of $8.25 million. Underwriters Van Kasper & Co., of SanFrancisco, and Gerard Klauer Mattison & Co. LLC, of New York,have options to buy another 330,000 shares to cover overallotments.
* Quintiles Transnational Corp., of Research Triangle Park, N.C.,completed its acquisition of PMC Contract Research AB, of Uppsala,Sweden. Quintiles issued 273,000 shares and paid $1.3 million incash for the takeover.
* T Cell Sciences Inc., of Needham, Mass., said results from a PhaseI trial of TP10, which is a complement inhibitor, showed thecompound was well-tolerated and the amount detected in the bloodwas directly proportional to the dose. The studies are evaluatingTP10, recombinant soluble complement receptor 1, for first-timeacute heart attack patients. The drug also is in Phase II trials for adultrespiratory distress syndrome.
(c) 1997 American Health Consultants. All rights reserved.